Ken Griffin’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-33,766
| Closed | -$268K | – | 14217 |
|
|
2025
Q2 | $268K | Buy |
+33,766
| New | +$151K | ﹤0.01% | 10054 |
|
|
2025
Q1 | – | Sell |
-1,507,192
| Closed | -$2.56M | – | 15639 |
|
|
2024
Q4 | $2.56M | Buy |
1,507,192
+64,724
| +4% | +$191K | ﹤0.01% | 5131 |
|
|
2024
Q3 | $4.9M | Sell |
1,442,468
-691
| -0% | -$2.56K | ﹤0.01% | 3980 |
|
|
2024
Q2 | $5.77M | Sell |
1,443,159
-722,652
| -33% | -$2.47M | ﹤0.01% | 3526 |
|
|
2024
Q1 | $7.39M | Buy |
2,165,811
+3,909
| +0.2% | +$12.2K | ﹤0.01% | 3366 |
|
|
2023
Q4 | $7.31M | Sell |
2,161,902
-4,211
| -0.2% | -$21.7K | ﹤0.01% | 3259 |
|
|
2023
Q3 | $11.7M | Sell |
2,166,113
-14,211
| -0.7% | -$98.2K | ﹤0.01% | 2488 |
|
|
2023
Q2 | $20.5M | Buy |
2,180,324
+18,528
| +0.9% | +$175K | ﹤0.01% | 1851 |
|
|
2023
Q1 | $21.2M | Sell |
2,161,796
-2,120
| -0.1% | -$23.8K | ﹤0.01% | 1865 |
|
|
2022
Q4 | $27M | Sell |
2,163,916
-2,551
| -0.1% | -$31.3K | 0.01% | 1650 |
|
|
2022
Q3 | $19.7M | Buy |
2,166,467
+1,431
| +0.1% | +$10.5K | ﹤0.01% | 1889 |
|
|
2022
Q2 | $5.47M | Buy |
2,165,036
+2,397
| +0.1% | +$9.47K | ﹤0.01% | 3629 |
|
|
2022
Q1 | $14.9M | Buy |
+2,162,639
| New | +$28.5M | ﹤0.01% | 2379 |
|
Other funds holding VIGL
Ken Griffin's VIGL Position: Q3 2025 in Review
Ken Griffin sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 33,766 shares — an estimated $268K sold.
Ken Griffin first reported a position in VIGL in Q1 2022 and held it in 13 quarters. The position peaked at $27M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Ken Griffin reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Ken Griffin sold 33,766 Vigil Neuroscience shares in Q3 2025, an estimated $268K.
- Ken Griffin first reported a position in Vigil Neuroscience in Q1 2022 and held it in 13 quarters.
- Ken Griffin's Vigil Neuroscience position peaked at $27M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.